bortezomib

FDA Drug Profile — Bortezomib, BORTEZOMIB, bortezomib, VELCADE

bortezomib is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including Bortezomib, BORTEZOMIB, bortezomib. Available dosage forms: powder, injection, injection, powder, lyophilized, for solution.

Drug details

Generic Name
bortezomib
Brand Names
Bortezomib, BORTEZOMIB, bortezomib, VELCADE
Application Number
NDA215331
Sponsor
Cilag AG
NDC Codes
12
Dosage Forms
POWDER, INJECTION, INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes
INTRAVENOUS, SUBCUTANEOUS
Active Ingredients
BORTEZOMIB

Indications and Usage

1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.